<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424018</url>
  </required_header>
  <id_info>
    <org_study_id>111-302</org_study_id>
    <secondary_id>2017-002404-28</secondary_id>
    <nct_id>NCT03424018</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia</brief_title>
  <official_title>A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for
      the treatment of children with Achondroplasia
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baselines in mean annualized growth velocity</measure>
    <time_frame>Up to 5 years or near final adult height</time_frame>
    <description>Long term efficacy as measured by change in annualized growth velocity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potential changes in health-related quality of life as measured by the Quality of Life in Short-Statured Youth questionnaire</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential changes in daily activity performance as measured by Activities of Daily Living questionnaire</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize maximum concentration (Cmax) of BMN 111 in plasma</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the area under the plasma concentration time-curve from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the area under the plasma concentration time-curve from time 0 to the last measurable concentration (AUC0-t)</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the elimination half-life of BMN 111 (t1⁄2)</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the apparent clearance of drug</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the apparent volume of distribution based upon the terminal phase (Vz/F)</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the amount of time BMN 111 is present at maximum concentration (Tmax)</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate sleep study scores by polysomnography</measure>
    <time_frame>Week 260</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate change from baseline in body proportion ratios of the extremities</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BMN 111 Activity Biomarkers</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
    <description>BMN 111 activity will be assessed by measuring bone and collagen metabolism</description>
  </other_outcome>
  <other_outcome>
    <measure>Optional exploratory genomic biomarker analysis</measure>
    <time_frame>Week 260</time_frame>
    <description>Exploratory genomic analysis of genes associated with CNP signaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of BMN 111 on bone morphology and quality</measure>
    <time_frame>Through study completion, every 6 months</time_frame>
    <description>The effect of BMN 111 on bone morphology will be assessed by measuring bone mineral density via Dual X-ray Absorptiometry</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Achondroplasia</condition>
  <arm_group>
    <arm_group_label>BMN 111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMN 111</intervention_name>
    <description>Subcutaneous injection of 15 μg/kg of BMN 111 daily</description>
    <arm_group_label>BMN 111</arm_group_label>
    <other_name>Vosoritide</other_name>
    <other_name>Modified recombinant human C-type natriuretic peptide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have completed Study 111-301

          -  Female &gt;= 10 years old or who have begun menses must have a negative pregnancy test at
             the Baseline Visit and be willing to have additional pregnancy tests during the study

          -  If sexually active, willing to use a highly effective method of contraception while
             participating in the study

          -  Are willing and able to perform all study procedures as physically possible

        Exclusion Criteria:

          -  Permanently discontinued BMN 111 or placebo during the 111-301 study

          -  Have a clinically significant finding or arrhythmia on Baseline ECG that indicates
             abnormal cardiac function

          -  Evidence of growth plate closure obtained at Baseline Visit

          -  Require any investigational agent prior to completion of study period

          -  Current therapy with medications known to alter renal function

          -  Planned or expected bone/limb surgery during the study period

          -  Fracture of the long bones or spine in the 6 months preceding the Baseline Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/achondroplasia</url>
    <description>NIH Genetics Home Reference related topics: Achondroplasia</description>
  </link>
  <link>
    <url>https://rarediseases.info.nih.gov/diseases/8173/achondroplasia</url>
    <description>Description NIH Genetic and Rare Diseases Information Center resources: Achondroplasia</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACH</keyword>
  <keyword>Achondroplasia</keyword>
  <keyword>Bone Diseases</keyword>
  <keyword>Bone Diseases, Developmental</keyword>
  <keyword>Dwarfism</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Natriuretic Agents</keyword>
  <keyword>Natriuretic Peptide, C-Type</keyword>
  <keyword>Osteochondrodysplasias</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Skeletal Dysplasias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achondroplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, C-Type</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

